RPTX reparerx.com Net earnings per share growth forecast for next year

Corporate company logo of Repare Therapeutics Inc (RPTX)

The use of a synthetic lethality platform enables Repare Therapeutics (RPTX) to establish long-term patents for targeted drugs. Analyst 12-month EPS growth targets indicate a metric value of 0.00. The diversification of DNA damage targets within the pipeline mitigates risks, while professional management under Lloyd Sigal ensures a stable financial position and the continuity of the R&D strategy.

RPTX: Repare Therapeutics, Inc. Net earnings per one share growth forecast for next year 07/04/2022 - 02/07/2026

Financial and market metric breakdowns for Repare Therapeutics Inc. (RPTX)

- share price and consensus valuation forecast:
Stock Price Repare Therapeutics Inc|RPTX - Analyst Consensus Forecast
- market capitalization data:
Market Value Repare Rx|RPTX - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share Repare Therapeutics|RPTX - Book Value of Business|Market Capitalization to Book Value Ratio reparerx.com|RPTX - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Repare Therapeutics|RPTX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital reparerx.com|RPTX - Company Cumulative Debt|Debts to Book Capitalization Repare Therapeutics Inc|RPTX - Company Long-Term Indebtedness|Company Current Liabilities Repare Therapeutics|Quick Liquidity Indicator reparerx.com
- earnings and valuation multiples information:
RPTX - Profit After Payment of Taxes|Projected Future Earnings Repare Therapeutics|RPTX - Company Value to Net Income|Forward P/E Multiple Repare Therapeutics Inc|RPTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Repare Rx|RPTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Repare Therapeutics|RPTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months reparerx.com|RPTX - Earnings per share trend in current year|Expected earnings per share growth for next year Repare Therapeutics
- sales and revenue data:
RPTX - Company Total Revenue|Company Projected Revenue Repare Therapeutics|RPTX - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Repare Therapeutics
Fundamental company analysis:Repare Therapeutics Inc., RPTX
Brand item of reparerx.com

For the biotechnology sector, where Repare Therapeutics focuses on synthetic lethality, expected profit dynamics serve as a key indicator of market value. This consensus EPS forecast benchmark for the coming year, valued at 0.00, aggregates current institutional analyst models regarding changes in net income per share. Growth in this metric confirms the success of clinical trials and the potential for acquisition by a tech giant, signaling the business's transition to a stage of financial stability.

Competing companies

GMAB (Genmab Corp) - Earnings growth forecast for next year|Earnings growth forecast for next year exelixis.com|Net earnings per share growth forecast for next year Nuvalent (NUVL)|KYMR (Kymera) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences Inc)|Net earnings per one share growth forecast for next year Enliven Pharma|ORIC Pharmaceuticals Inc - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Therapeutics, Inc.|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (verastem.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year Monte Rosa Tx GLUE|Earnings growth forecast for next year CGEM|Immuneering - Projected earnings per share growth rate for next year|C4 Therapeutics - Expected earnings per share growth for next year|Expected earnings per share trend next year BDTX|PMVP: Expected earnings per share growth for next year|karyopharm.com - Projected earnings per share increase next year|PPCB: Earnings growth forecast for next year|Bio Green Med Solution Inc - Expected earnings per share trend next year|AADI (Aadi Bioscience Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year aileronrx.com ALRN|Net earnings per share growth forecast for next year Blueprint Medicines Corp. (BPMC)|GLYC (GlycoMimetics) - Expected earnings per share trend next year|Earnings growth forecast for next year SWTX (SpringWorks Therapeutics, Inc)